ESPR Esperion Therapeutics, Inc.

+0.09  (0%)
Previous Close 33.19
Open 33.36
Price To book 3.90
Market Cap 751.80M
Shares 22,590,000
Volume 290,254
Short Ratio 3.17
Av. Daily Volume 1,997,910

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced March 7, 2017. Data due 4Q 2017.
Bempedoic Acid/ Ezetimibe/ Atorvastatin (1002-038)
Phase 2 (PK/PD) top-line data met primary endpoint - October 2016.
Bempedoic acid (ETC-1002-035)
Patients treated with high-dose statin therapy
Phase 3 initiation of efficacy trials announced January 8, 2017. Data due mid 2018.
Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048
Hypercholesterolemia - statin intolerance
Phase 3 long-term safety and tolerability trial initiated January 2016. Completion of enrollment announced January 25, 2017. Top-line results due 2Q 2018.
Bempedoic acid (ETC-1002-040)
Hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins
Phase 2 data released July 2015
Bempedoic acid ETC-1002-014
Hypercholesterolemia and hypertension

Latest News

  1. Esperion Provides Update on Common Stock Trading Activity
  2. Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
  3. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  4. Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
  5. Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics
  6. Why Esperion Therapeutics Shares Were Flat In April
  7. Esperion Therapeutics reports 1Q loss
  8. Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
  9. 3 Best Biotech Stocks During Trump's First 100 Days
  10. Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top
  11. 3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich
  12. Cramer's lightning round: I may be alone on this, but this e-commerce play is going higher
  13. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  14. 3 of the Best & Worst Performing Drug Stocks of Q1
  15. Could Pfizer Buy Esperion Therapeutics?
  16. The 3 Best Cholesterol Drug Stocks to Buy in 2017
  17. Which Biotechs Are Buyable As Sector Recovers In 2017?
  18. 5 Top Performing Stocks of the Best ETF of Q1
  19. Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference